Treatment News

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News


October 31, 2006
New Treatment Guidelines for HIV-Positive Children
The U.S. Department of Health and Human Services (DHHS) has completely revised its treatment guidelines for HIV-positive children. 
October 30, 2006
Progression-Free Survival Common For Pregnant Women
For pregnant HIV-infected women with access to highly active antiretroviral therapy (HAART), the medium-term postpartum prognosis is good, according to a report in the October 1st Journal of Acquired Immune Deficiency Syndromes.
October 27, 2006
Tyzeka Approved for Hepatitis B
The U.S. Food and Drug Administration (FDA) granted approval on Wednesday to Tyzeka? (telbivudine), a new treatment for chronic hepatitis B virus (HBV) infection. 
October 26, 2006
Vaccine Series Safe In Children
Pneumococcal conjugate vaccine (PCV) followed by pneumococcal polysaccharide vaccine (PPV) appears to be safe and effective for certain HIV-infected children, researchers report in the October issue of the Pediatric Infectious Disease Journal.
October 24, 2006
Vulnerable HIV Patients Less Likely To Have Care
Members of minority groups, who are most at risk of contracting HIV infection and most likely to be in greatest need of service, are also the individuals who are least likely to be receiving medical care in the U.S., investigators report.
October 23, 2006
Enfuvirtide As Rescue Therapy in Med-Experienced
Findings from a small study suggest that the fusion inhibitor enfuvirtide (formerly T-20) is a useful therapeutic option for multi-class experienced HIV-infected patients.
Enfuvirtide As Rescue Therapy
Findings from a small study suggest that the fusion inhibitor enfuvirtide (formerly T-20) is a useful therapeutic option for multi-class experienced HIV-infected patients.
October 20, 2006
New 300mg Reyataz Capsule Approved
Bristol-Myers Squibb announced today that it has received U.S. Food and Drug Administration (FDA) approval for a 300mg capsule version of its protease inhibitor Reyataz® (atazanavir). For HIV-positive people combining Reyataz with Norvir® (ritonavir), the 300mg Reyataz capsule can be used in place of the two 150mg capsules currently recommended when both drugs are taken together.
October 19, 2006
AIDS activist with baboon marrow transplant dies
The California AIDS activist who received the first bone marrow transplant from a baboon in a desperate bid to combat the disease died this past week, his partner of 26 years said on Sunday.
Anal HPV Infection Common in Women
Human papillomavirus (HPV) infection of the anus is more common than HPV infection of the cervix in HIV-positive women, according to new data reported last week at the 44th Annual Meeting of the Infectious Disease Society of America (IDSA) in Toronto.
October 16, 2006
Diet and Exercise Fight Metabolic Syndrome
A new study suggests that improvements in diet and exercise can help manage some of the signs and symptoms of the "metabolic syndrome" in people with HIV.
AIDS Activist With Baboon Marrow Transplant Dies
The California AIDS activist who received the first bone marrow transplant from a baboon in a desperate bid to combat the disease died this past week, his partner of 26 years said on Sunday.
October 11, 2006
Bacteria Protein Prevents HIV Entry
The binding domain from Porphyromonas gingivalis gingipain prevents cell entry by HIV-1, according to a report in the September issue of Antimicrobial Agents and Chemotherapy.
October 10, 2006
New U.S. Treatment Guidelines
Norvir (ritonavir)-boosted Reyataz (atazanavir) and Lexiva (fosamprenavir) are comparable to Kaletra (lopinavir/ritonavir) as "preferred" protease inhibitor (PI) options for HIV-positive people starting therapy for the first time, according to new federal treatment guidelines issued by the U.S. Department of Health and Human Services (DHHS).
Tenofovir Prodrug Delays SHIV Infection
Nearly two-thirds of patients with HIV-associated dementia have actively changing cognitive status; the neurological status in the majority of these patients deteriorates but a significant minority improves, according to data presented here at the annual meeting of the American Neurological Association.
Course Of HIV Neurologic Disease Variable, Related To Platelet Count
Nearly two-thirds of patients with HIV-associated dementia have actively changing cognitive status; the neurological status in the majority of these patients deteriorates but a significant minority improves, according to data presented here at the annual meeting of the American Neurological Association.
October 06, 2006
First Test for Early HIV Infection
The U.S. Food and Drug Administration has announced the approval of Aptima®, a new assay that can be used to aid the detection of HIV in those who may be newly infected with the virus and cannot yet depend on the results of antibody testing.
Diary of a Doc: Vaccine Update at ICAAC
Developing a vaccine to prevent HIV infection has been a significant challenge, and, sadly, traditional vaccines are not expected to reach clinical use for another ten years.
Animal Study Indicates Alcohol May Accelerate HIV Progression
Simian immunodeficiency virus (SIV) disease appears to progress more rapidly in rhesus macaques that have been regularly subjected to ethanol intoxication, researchers report. They say the effect could be similar in people infected with HIV.
October 05, 2006
Medecins Sans Frontieres Founder Wants Stronger WHO
The United Nations cannot take a backseat to private philanthropic foundations and needs more money to combat diseases like malaria and tuberculosis, the French candidate to lead the World Health Organisation (WHO) said on Thursday.
Boosted Atazanavir Of Mixed Benefit In Pediatric HIV
Switching to a once daily-regimen including ritonavir-boosted atazanavir appears helpful in some HIV-infected children, but has led to unexpected virological failure in others, according to French researchers
October 03, 2006
ICAAC: Trizivir vs. Reyataz/Combivir
A new study suggests that 48 weeks of treatment with Trizivir® is comparable to a protease inhibitor-based regimen.
October 02, 2006
ICAAC: Norvir-Boosted Lexiva vs. Reyataz
Early data from a study comparing Lexiva (fosamprenavir) to Reyataz (atazanavir), both combined with low-dose Norvir (ritonavir), suggest that both drugs have similar effectiveness.
More Treatment News

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.

Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ



Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Are you buying holiday gifts that raise HIV/AIDS awareness?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.